EMA Spells Out Disclosure Policy for Clinical Data Set for Publication
Drugmakers submitting anonymized clinical data in applications to the EMA must keep up on technology advances that could put that data at risk for re-identification.
Source: International Pharmaceutical Regulatory Monitor